Clinical Trials Logo

Clinical Trial Summary

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of Hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of Hyperuricemia through several mechanisms. This trial aims to examine its protective effect in humans.


Clinical Trial Description

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids. However, whether administration of prebiotics also has a protective effect in subjects with Hyperuricemia remain unknown. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05385003
Study type Interventional
Source Sun Yat-sen University
Contact Min Xia, PhD
Phone +86-20-87332433
Email xiamin@mail.sysu.edu.cn
Status Recruiting
Phase N/A
Start date May 14, 2022
Completion date December 31, 2023